These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869 [TBL] [Abstract][Full Text] [Related]
9. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer. Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214 [TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. Garcia-Rodriguez J; Fernandez-Gomez JM; Cozar JM; Miñana B; Gomez-Veiga F; Rodriguez-Antolin A; ; Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):156-163. PubMed ID: 32113829 [TBL] [Abstract][Full Text] [Related]
12. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
13. [Metastatic hormone-sensitive prostate cancer: more than just androgen-deprivation therapy]. Mechahougui H; Achard V; Friedlaender A Rev Med Suisse; 2020 May; 16(695):1098-1101. PubMed ID: 32462838 [TBL] [Abstract][Full Text] [Related]
14. Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. Ferraldeschi R; Pezaro C; Karavasilis V; de Bono J Annu Rev Med; 2013; 64():1-13. PubMed ID: 23020876 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Karantanos T; Corn PG; Thompson TC Oncogene; 2013 Dec; 32(49):5501-11. PubMed ID: 23752182 [TBL] [Abstract][Full Text] [Related]
16. Reconsideration of progression to CRPC during androgen deprivation therapy. Mizokami A; Namiki M J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975 [TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged? Singer EA; Golijanin DJ; Messing EM Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491 [TBL] [Abstract][Full Text] [Related]
18. Intra-prostatic androgen levels during various androgen-blockade regimens. Nishiyama T Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782 [TBL] [Abstract][Full Text] [Related]